WAKE-UP CALL: 104m Indians or 11% of the population suffer from obstructive sleep apnea, according to a 2023 AIIMS study ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 483.76% and ...

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

The third ‘Downton Abbey’ film honors the late Dame Maggie Smith and her iconic portrayal of Violet Crawley. The drug is ...

During FDA-declared shortages, pharmacists can legally make compounded versions of brand-name medications. But drugmakers and ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

GLP-1 receptor agonist weight loss drugs can negatively interact with eating disorder psychopathology and treatment in ...

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).